EOS Imaging receives FDA clearance for Micro Dose

EOS Imaging recently announced that the FDA has cleared the Micro Dose feature for pediatric imaging.

According to initial study results presented at the French Society of Radiology’s annual meeting in 2013 and the Radiological Society of North America’s annual meeting in 2014, the Micro Dose feature generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2-D and 3-D follow-up examinations.

Micro Dose is meant to address an important medical need for pediatric patients who are sensitive to adverse effects associated with excessive exposure to radiation. This is particularly important in pediatric patients with scoliosis, who require frequent imaging sessions to track treatment progression that can, in turn, increase the risk of radiation-induced cancer later in life, according to a company press release.

Reference: www.eos-imaging.com.

EOS Imaging recently announced that the FDA has cleared the Micro Dose feature for pediatric imaging.

According to initial study results presented at the French Society of Radiology’s annual meeting in 2013 and the Radiological Society of North America’s annual meeting in 2014, the Micro Dose feature generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2-D and 3-D follow-up examinations.

Micro Dose is meant to address an important medical need for pediatric patients who are sensitive to adverse effects associated with excessive exposure to radiation. This is particularly important in pediatric patients with scoliosis, who require frequent imaging sessions to track treatment progression that can, in turn, increase the risk of radiation-induced cancer later in life, according to a company press release.

Reference: www.eos-imaging.com.